Medicine composition containing vitamin D and metformin

• US 9,333,210 B2
• Filed: 08/17/2011
• Issued: 05/10/2016
• Est. Priority Date: 02/11/2011
• Status: Active Grant

• Current Assignee: Guangdong Taihe Medicine Science & Technology Co., Ltd
• Original Assignee: Guangdong Taihe Medicine Science & Technology Co., Ltd
• Inventors: Fan, Fulin
• Primary Examiner(s): QAZI, SABIHA NAIM
• Application Number:
  US13/980,019
• Publication Number:
  US 20140031322A1
• Time in Patent Office: 1,728 Days
• Field of Search: 514/167
• US Class Current: 1/1
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/155 Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• CPC Class Codes: A61K 31/59 Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
• CPC Class Codes: A61K 31/592 9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
• CPC Class Codes: A61K 31/593 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A medicine composition contains vitamin D and metformin, wherein vitamin D comprises vitamin D2, vitamin D3, alphacalcidol, calcifediol, calcitriol, and dihydrotachysterol. The composition can be used in the preparation of a medicine for treating and/or preventing a polyp and cancer in large intestine.

Claims

1. A pharmaceutical composition for treating and/or preventing colonic polyps or colorectal cancer, consisting of a synergistic combination of (a):

vitamin D3;

and (b) metformin or a pharmaceutically acceptable salt thereof; and

(c) a pharmaceutical acceptable carrier;

wherein the ratio (International Unit;

mg) of (a) to (b) is between 1;

12 and 15;

2.

2. The pharmaceutical composition according to claim 1, wherein the pharmaceutically acceptable salt of metformin is metformin hydrochloride.

3. The pharmaceutical composition according to claim 1, wherein the ratio (International Unit:

mg) of (a) to (b) is 1;

4, 5;

6 or 5;

2.

4. The pharmaceutical composition according to claim 1, wherein the ratio (U:

mg) of (a) to (b) is 1;

4 to 5;

2.

5. The pharmaceutical composition according to claim 1, wherein the total amount of (a) and (b) is 1-99 wt % of the composition.

6. The pharmaceutical composition according to claim 1, wherein the composition is in oral dosage form.

7. A method for treating and/or preventing colorectal polyps and colorectal cancer, comprising administrating to a mammal in need thereof a pharmaceutical composition according to claim 1.

8. The method according to claim 7, wherein the pharmaceutical composition is administrated once or twice a day, or administrated once every other day in a sustained-release manner.

9. The method according to claim 7, wherein the pharmaceutical composition is administrated by oral administration.

10. The method according to claim 7, where the ratio (U:

mg) of active ingredient (a) to active ingredient (b) is 1;

4 to 5;

2.